- Home
- SLSR vs FLGT Comparison
SLSR vs FLGT Comparison
Compare SLSR & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- FLGT
- Stock Information
- Founded
- SLSR 2018
- FLGT 2011
- Country
- SLSR Switzerland
- FLGT United States
- Employees
- SLSR N/A
- FLGT N/A
- Industry
- SLSR
- FLGT Medical Specialities
- Sector
- SLSR
- FLGT Health Care
- Exchange
- SLSR NYSE
- FLGT Nasdaq
- Market Cap
- SLSR 539.0M
- FLGT 588.5M
- IPO Year
- SLSR N/A
- FLGT 2016
- Fundamental
- Price
- SLSR $4.75
- FLGT $19.91
- Analyst Decision
- SLSR Buy
- FLGT Buy
- Analyst Count
- SLSR 2
- FLGT 2
- Target Price
- SLSR $11.00
- FLGT $24.00
- AVG Volume (30 Days)
- SLSR 35.4K
- FLGT 222.9K
- Earning Date
- SLSR 08-08-2025
- FLGT 08-01-2025
- Dividend Yield
- SLSR N/A
- FLGT N/A
- EPS Growth
- SLSR N/A
- FLGT N/A
- EPS
- SLSR N/A
- FLGT N/A
- Revenue
- SLSR N/A
- FLGT $292,448,000.00
- Revenue This Year
- SLSR N/A
- FLGT $11.79
- Revenue Next Year
- SLSR N/A
- FLGT $10.45
- P/E Ratio
- SLSR N/A
- FLGT N/A
- Revenue Growth
- SLSR N/A
- FLGT 1.71
- 52 Week Low
- SLSR $1.90
- FLGT $14.57
- 52 Week High
- SLSR $4.76
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- SLSR 57.43
- FLGT 46.90
- Support Level
- SLSR $4.36
- FLGT $19.41
- Resistance Level
- SLSR $4.72
- FLGT $19.67
- Average True Range (ATR)
- SLSR 0.18
- FLGT 0.62
- MACD
- SLSR -0.01
- FLGT -0.14
- Stochastic Oscillator
- SLSR 72.09
- FLGT 28.99
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.